NuVasive, Inc. Sued by Investor

SAN DIEGO, Sept. 3, 2013

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

NuVasive Accused of Making False and Misleading Statements

According to the complaint, certain NuVasive officers made false and misleading statements and failed to disclose information regarding the company's operation, and business prospects.  Specifically, the complaint alleges that, throughout the Class Period, the company and certain of its officers disseminated false and misleading statements and/or failed to disclose that company failed to maintain an effective compliance program as set forth by the U.S. Department of Health and Human Services ("HHS").  Further, because the company lacked an effective compliance program, NuVasive failed to detect that the company had been violating the False Claims Act by submitting false claims to Medicare and Medicaid.  As a result of the foregoing, NuVasive shares traded at artificially inflated prices during the Class Period.

NuVasive Stock Drops on News of HHS Investigation

On July 30, 2013, according to the complaint, NuVasive disclosed in a regulatory filing that the company was being investigated by the HHS and had received a subpoena requesting documents for the period January 2007 through April 2013.  The subpoenaed documents relate to the agency's investigation into possible false claims submitted by NuVasive to Medicare and Medicaid.  On this news, NuVasive shares dropped 12%, or $3.28 per share, to close at $22.84 on July 31, 2013.

If you invested in NuVasive and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, ddonahue@robbinsarroyo.com, or via the shareholder information form  on the firm's website.